Imfinzi approved in the EU in patients with early gastric and gastroesophageal cancers March 17, 2026
NMPA Accepts New Drug Applications for Toripalimab Subcutaneous Injection Across 12 Indications March 10, 2026
Ziihera (zanidatamab-hrii) Results in 1L HER2+ Locally Advanced or Metastatic GEA Announced Including 2+ Years Median OS Benefit January 11, 2026
BostonGene and Kyoto University to develop advanced biological signatures to enhance targeted treatment strategies for ESCC November 18, 2025
First patient dosed in the SPaCE-MT trial of MT-302 with CAPOX with or without nivolumab or trastuzumab in 1L advanced gastroesophageal cancer November 4, 2025
Alignment with FDA obtained on study design to advance two Ph 3 trials in gastroesophageal cancers (FAPI-GO) and PDAC (FAPI-PRO), with [18F] FAPI-74 October 7, 2025
Data from Ongoing Dose Escalation of BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma presented July 8, 2025
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for CLDN18.2-targeting ADC XNW27011 June 3, 2025
IDeate-Esophageal01 Ph 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma May 21, 2025
Sandoz enters global collaboration license agreement with Henlius to commercialize ipilimumab in multiple indications May 6, 2025
TEVIMBRA Approved in U.S. for 1L Treatment of Advanced ESCC in Combination with Chemotherapy March 11, 2025
FAILED TRIAL: Ph 3 LEAP-015 Trial of KEYTRUDA, LENVIMA, Chemo combo in Patients with HER2-neg Gastroesophageal Adenocarcinoma did not meet co-primary endpoint of OS January 28, 2025
TEVIMBRA Approved in US for 1L Treatment of Gastric and GEJ Cancers in Combination with Chemotherapy December 31, 2024
European Commission Approves TEVIMBRA for 1L Treatment of Advanced/Metastatic ESCC and Gastric or GEJ Cancer December 3, 2024
First patient dosed in Ph 3 trial HLX22-GC-301 of HLX22 in combination with trastuzumab and chemo in 1L HER2+ve advanced G/GEJ cancer patients November 26, 2024
UK MHRA approved toripalimab (LOQTORZI®)-chemo combos for the 1L treatment of metastatic NPC and unresectable advanced, recurrent, or metastatic ESCC November 19, 2024
VYLOY (zolbetuximab-clzb) Approved by US FDA for Treatment of Advanced Gastric and GEJ Cancer October 22, 2024
Positive CHMP Opinions for TEVIMBRA® as a 1L Treatment for Advanced/Metastatic Gastric or GEJ Cancer and Esophageal Squamous Cell Carcinoma October 22, 2024
FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers October 8, 2024
EC approved toripalimab (LOQTORZI®) for the treatment of certain patients with mNPC and ESCC October 2, 2024
FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers recommends a class-wide PD-L1 expression level cut-off across PD-1 inhibitors October 1, 2024
